Ultragenyx cuts 20% of staff after rare disease drug setbacks

Ultragenyx said it will lay off around 20% of its staff after halting development of two rare disease drug candidates, according to STAT. The announcement comes as the company faces setbacks in its research pipeline.

This move signals ongoing cost pressures and the challenge of managing high-risk drug development in the biotech sector. Pharma leaders may need to reassess their own project portfolios and workforce strategies in response to shifting market and research realities.